All In Biotech

Drug Trial Radar · NCT02294630

Aerosolized Surfactant in Neonatal RDS

Aerosolized Survanta in Neonatal Respiratory Distress Syndrome: Phase I/II Study

Last checked: Nov 19, 2026Latest source record: Aug 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 159 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

159

Actual

Start

Dec 2014

Primary completion

Jul 2019

Study completion Jul 2020

Sponsor

Lead sponsor
Sood, Beena G., MD, MSIndividual
Sponsor type
Individual
First posted
Nov 19, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, up to 24 hours
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Respiratory distress syndrome (RDS), caused by surfactant deficiency, is the leading cause of mortality and morbidity in preterm infants. Intratracheal instillation, the only approved means of surfactant delivery, requires endotracheal intubation and mechanical ventilation with their attendant risks. Interventions that decrease need for intubation and mechanical ventilation like noninvasive ventilation (NIV) including nasal continuous positive airway pressure, high flow nasal cannula or nasal intermittent mandatory ventilation are increasingly being used for initial respiratory support in preterm neonates with RDS to improve outcomes. Aerosolized surfactant delivered during NIV is an innovative and promising concept for the treatment of RDS - retaining the advantages of early surfactant with alveolar recruitment while obviating the risks of intubation and mechanical ventilation. The investigators overall hypothesis is that treatment of RDS with aerosolized surfactant in preterm infants undergoing NIV is safe and feasible and will result in short-term improvement in oxygenation and ventilation. The objective of this proposal is to perform a single-center unblinded Phase II randomized clinical trial of aerosolized surfactant for the treatment of RDS in preterm neonates undergoing NIV. Funding Source - FDA-OOPD.

Conditions

  • Respiratory Distress Syndrome, Newborn

Interventions

  • SurfactantDrug

    Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events as a Measure of Safety and FeasibilityTime frame: During and within 6 hours after end of study drug administration, expected maximum of approximately 14 hours
  2. Patient Status as Evaluated by Dose LevelTime frame: During study drug administration, expected maximum of approximately 8 hours for adverse effects and infant comfort; need for intubation was assessed within 72 hours of study intervention.
  3. Short Term Efficacy as Assessed by Need for IntubationTime frame: Within 72 hours of study intervention

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hutzel Women's Hospital

    Detroit, Michigan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.